NASDAQ · HRTX
Healthcare · Biotechnology
$0.37
Down-$0.04 (-10.35%)
Updated Oct 6, 2026, 11:28 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HRTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
HRTX closed at $0.37 after 20 trading sessions, up 5.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.359 | $0.3834 | $0.353 | $0.37 | 2.94M |
| Oct 2, 2026 | $0.36 | $0.405 | $0.34 | $0.3476 | 4.08M |
| Oct 1, 2026 | $0.3151 | $0.3599 | $0.3129 | $0.3559 | 3.18M |
| Sep 30, 2026 | $0.3068 | $0.3429 | $0.30 | $0.3135 | 2.47M |
| Sep 29, 2026 | $0.2918 | $0.32 | $0.2857 | $0.306 | 3.36M |
| Sep 28, 2026 | $0.29 | $0.296 | $0.28 | $0.2918 | 1.12M |
| Sep 25, 2026 | $0.29 | $0.30 | $0.28 | $0.2942 | 1.57M |
| Sep 24, 2026 | $0.2968 | $0.2989 | $0.28 | $0.29 | 929.85K |
| Sep 23, 2026 | $0.298 | $0.2996 | $0.2847 | $0.291 | 1.72M |
| Sep 22, 2026 | $0.2771 | $0.306 | $0.2716 | $0.299 | 3.87M |
| Sep 21, 2026 | $0.31 | $0.3102 | $0.261 | $0.27 | 8.59M |
| Sep 18, 2026 | $0.3162 | $0.3171 | $0.3075 | $0.3097 | 3.95M |
| Sep 17, 2026 | $0.33 | $0.33 | $0.307 | $0.3157 | 916.76K |
| Sep 16, 2026 | $0.3154 | $0.321 | $0.3101 | $0.3178 | 1.11M |
| Sep 15, 2026 | $0.3095 | $0.3168 | $0.306 | $0.314 | 1.5M |
| Sep 14, 2026 | $0.3155 | $0.3199 | $0.307 | $0.3153 | 1.17M |
| Sep 11, 2026 | $0.33 | $0.3312 | $0.3114 | $0.3155 | 1.37M |
| Sep 10, 2026 | $0.33 | $0.3311 | $0.3207 | $0.3223 | 1.13M |
| Sep 9, 2026 | $0.3427 | $0.3507 | $0.33 | $0.333 | 1.79M |
| Sep 8, 2026 | $0.348 | $0.355 | $0.33 | $0.35 | 1.06M |
The latest Smart Investors Daily articles mentioning HRTX.
Company
Market Activity
Research & News
HRTX research
Company profile and research snapshot.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2026 | Needham | Hold | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 8, 2025 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License
Benzinga · Aug 11, 2026
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
SeekingAlpha · Aug 10, 2026
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call August 10, 2026 8:30 AM EDTCompany ParticipantsMelissa Jarel - Vice President of LegalCraig Collard -...
Benzinga · Aug 10, 2026
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HRTX.
